D
Jazz Pharmaceuticals plc JAZZ
$139.48 $2.271.65% NASDAQ
Recommendation
Prev Close
$127.00
Volume
1,344
Avg Vol (90D)
748,345
Market Cap
$7.70B
Dividend & Yield
--
52-Week Range
$95.49 - $148.06
P/E (TTM)
--
EPS (TTM)
-$6.73
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 2,000 Shares of Stock
10/6/2025 - Ticker Report
Are Shares of Jazz Pharmaceuticals Set for Growth After Strong Q2 Results in 2025?
10/5/2025 - Simply Wall St
Robeco Institutional Asset Management B.V. Sells 92,794 Shares of Jazz Pharmaceuticals PLC $JAZZ
10/5/2025 - MarketBeat
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Recommendation of "Moderate Buy" from Analysts
10/5/2025 - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $263,560.00 in Stock
10/4/2025 - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Bruce Cozadd Sells 3,500 Shares
10/4/2025 - MarketBeat
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 2,000 Shares of Stock
10/4/2025 - MarketBeat
Insider Sell: Bruce Cozadd Sells 5,500 Shares of Jazz Pharmaceuticals PLC
10/4/2025 - GuruFocus
Why Jazz Pharmaceuticals (JAZZ) Is Up 7.4% After Groundbreaking FDA Approval for First-Line Lung Cancer Therapy
10/3/2025 - Simply Wall St
Deutsche Bank Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)
10/3/2025 - TipRanks Financial Blog
A Fresh Look at Jazz Pharmaceuticals (JAZZ) Valuation as New Xywav Data Reinforces Growth Prospects
10/3/2025 - Simply Wall St
fda approval jazz and roche combo sets new bar first line small cell lung cancer
10/3/2025 - FiercePharma
Jazz Pharma : FDA Approves Zepzelca + Tecentriq Combo For First-Line Maintenance In ES-SCLC Patients
10/3/2025 - Nasdaq News: Markets
FDA Approves Jazz Pharmaceuticals' (JAZZ) New Cancer Treatment Regimen
10/2/2025 - GuruFocus
Jazz Pharmaceuticals announces FDA approves Zepzelca in ES-SCLC
10/2/2025 - The Fly
FDA Approves Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
10/2/2025 - PR Newswire
FDA approves combo of Jazz's lurbinectedin and Roche's atezolizumab for ES-SCLC
10/2/2025 - TipRanks Financial Blog
Headlines Boost Pharma Stocks. Charts of Pfizer, Johnson & Johnson, Jazz Pharmaceuticals Speak to Rally Into Year End
10/1/2025 - Yahoo! Finance: News
Park Avenue Securities LLC Takes Position in Jazz Pharmaceuticals PLC $JAZZ
10/1/2025 - MarketBeat
State of Alaska Department of Revenue Boosts Stake in Jazz Pharmaceuticals PLC $JAZZ
9/29/2025 - MarketBeat
Are Jazz Pharmaceuticals Shares Set for a Rebound After Recent Drug Approval in 2025?
9/27/2025 - Simply Wall St
Piper Sandler Reaffirms Jazz Pharmaceuticals (JAZZ) Price Target Ahead of Trial Data
9/27/2025 - Insider Monkey
Affinity Wealth Management LLC Purchases New Position in Jazz Pharmaceuticals PLC $JAZZ
9/25/2025 - MarketBeat
Jazz Pharmaceuticals Announces Promising Xywav Data: Why I Assign A BUY Rating
9/24/2025 - Seeking Alpha - Long Ideas
Jazz Pharmaceuticals Announces Promising Xywav Data: Why I Assign A BUY Rating
9/24/2025 - SeekingAlpha
Income Statement
Total Revenue (TTM)
$4.09B
EBITDA (TTM)
$1.35B
EBIT (TTM)
$681.73M
Net Income (TTM)
-$404.84M
Balance Sheet
Total Assets (Q)
$10.94B
Total Debt (Q)
$5.43B
Total Liabilities (Q)
$7.24B
Book Value Per Share (Q)
$61.12
Cash Flow
Cash from Operations (TTM)
$1.32B
Cash from Investing (TTM)
-$789.15M
Cash from Financing (TTM)
-$699.84M
Net Change in Cash (TTM)
-$165.92M
Filings
Filing Date
Wednesday, August 6, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
0.53
7-Day Total Return
6.32%
30-Day Total Return
18.43%
60-Day Total Return
27.44%
90-Day Total Return
25.64%
Year to Date Total Return
12.70%
1-Year Total Return
25.74%
2-Year Total Return
6.29%
3-Year Total Return
10.18%
5-Year Total Return
-1.42%
52-week Low
Apr 09, 2025 - $95.49
52-week High
Feb 26, 2025 - $148.06
Valuation
Market Cap
$7.70B - Mid Cap
Enterprise Value
$11.47B
Price/Sales (TTM)
1.90
Price/Book (Q)
2.08
Dividends and Shares
Shares Outstanding
61.19
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.jazzpharma.com
Phone Number
353 1 634 7800
Address
Waterloo Exchange
Fifth Floor - Waterloo Road
Dublin 4 Dublin, D04 E5W7
Country
Ireland
Year Founded
2003
Business Description
Sector
--
Industry
--
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or... more
NASDAQ 10/03/2025 4:00PM Eastern Quotes delayed